On Thursday, Guggenheim reiterated its Buy rating on AnaptysBio (NASDAQ:ANAB) shares, maintaining confidence in the biotechnology company's prospects, particularly regarding its BTLA agonist, ANB032, which is in clinical development for atopic dermatitis (AD) and other autoimmune diseases (AIDs).
The analyst highlighted the potential of BTLA agonists in treating AIDs following the discontinuation of a similar asset by LLY. Despite this, the approach remains promising for conditions where B or T cells are implicated.
Gilead Sciences (NASDAQ:GILD) also featured BTLA-agonism in its inflammation pipeline, as discussed during its third-quarter earnings on Wednesday. Guggenheim's analysis suggests that both AnaptysBio and Gilead, which acquired a BTLA agonist through a $405 million acquisition of MiroBio, are developing potent BTLA agonists. AnaptysBio's ANB032 has shown to more effectively inhibit primary T cell proliferation compared to Gilead's molecule in clinical studies.
AnaptysBio has conducted a head-to-head comparison of ANB032 with other BTLA agonists, demonstrating promising results in a preclinical model of graft-versus-host disease. The management team at AnaptysBio has expressed high confidence in the upcoming Phase IIb study results for ANB032, indicating belief in the drug's efficacy based on analysis of blinded data.
The Phase IIb atopic dermatitis top-line results, expected in December, could position ANB032 as a strong competitor in the expected $10 billion market post-dupilumab. The analyst from Guggenheim foresees more than fourfold upside potential and less than 20% downside risk from the upcoming trial results, emphasizing the asymmetric risk/reward leading into the readout.
In other recent news, AnaptysBio has been the subject of various analyst revisions. H.C. Wainwright reduced its price target from $55.00 to $52.00, citing increased operating expenses and a third-quarter operating loss of $22.8 million. However, the company saw a significant increase in collaboration revenue, rising to $30 million in the third quarter.
Leerink Partners also trimmed their target price to $45, maintaining an Outperform rating due to AnaptysBio's robust portfolio and undervalued stock.
Guggenheim reiterated its Buy rating, expressing optimism for the upcoming Phase IIb atopic dermatitis readout of ANB032, AnaptysBio's BTLA agonist monoclonal antibody. Piper Sandler also maintained an Overweight rating on AnaptysBio, noting the potential success of the ongoing 28-week Phase 2b ROSETTA study for rosnilimab, a PD-1 agonist, in patients with moderate to severe Ulcerative Colitis.
AnaptysBio reported a third-quarter net loss of $32.9 million, with a cash and equivalents position of $458.0 million. The company's ANB032 is advancing to a Phase 2b ARISE-AD trial, and rosnilimab is proceeding to a Phase 2b RENOIR RA trial.
Positive results have also been reported from the GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab, a treatment for generalized pustular psoriasis. These are the recent developments in AnaptysBio's financial and clinical progress.
InvestingPro Insights
Recent InvestingPro data and tips offer additional context to AnaptysBio's (NASDAQ:ANAB) current position and future prospects. Despite the company's promising pipeline, particularly with ANB032, financial metrics reveal some challenges. AnaptysBio's revenue for the last twelve months as of Q3 2024 stands at $57.17 million, with a remarkable revenue growth of 282.17% over the same period. This aligns with the InvestingPro Tip that analysts anticipate sales growth in the current year.
However, the company is not yet profitable, with a negative gross profit margin of -131.38% and an operating income margin of -245.01% for the last twelve months. This is reflected in the InvestingPro Tip indicating that analysts do not anticipate the company to be profitable this year. Despite these financial challenges, AnaptysBio maintains a strong liquidity position, with liquid assets exceeding short-term obligations.
The stock's recent performance has been mixed, with a 34.44% price return over the past year, but a -32.7% return in the last month. This volatility is typical for biotechnology companies awaiting critical trial results. The upcoming Phase IIb atopic dermatitis results could significantly impact the stock's trajectory, as reflected in the analyst's optimistic outlook.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for AnaptysBio, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.